Sanofi finds itself in the midst of a snowballing crisis in the Philippines over its dengue vaccine, Dengvaxia, after the Southeast Asian country said that the product may be related to some deaths. But the French multinational has declined to refund Manila the amount spent on its public dengue vaccination program and turned down a request for an indemnification fund.
Will Sanofi’s Dengvaxia Woes Spiral Beyond The Philippines?
Sanofi appears to be under mounting pressure in the Philippines over deaths allegedly linked to its dengue vaccine and after declining to refund costs of the doses already used in the Southeast Asian nation’s vaccination plan. Whether or not the goings on could have a domino effect could be crucial for the product’s future.
More from Business
• By
In this week's episode: Trump’s drug pricing executive order; J&J says taxes, not tariffs, influence US manufacturing; Pfizer discontinuation sparks M&A speculation; US tariffs and manufacturing concentration; and tariffs’ pressures on pharma’s complex supply chain.
• By
Plus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.
• By
Cancer assets drove the highest percentage of biopharma alliance dealmaking in 2024, tripling the frequency of the next highest therapeutic category, neurology.
• By
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
More from Scrip
• By
The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.
• By
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
• By
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.